June 28, 2025

Get In Touch



Unichem Labs Gets USFDA Nod For Atenolol, Chlorthalidone Tablets

Mumbai: Drug maker, Unichem Laboratories Limited, has recently announced that the company has received Abbreviated New Drug Application (ANDA) approval for its Atenolol and Chlorthalidone Tablets, USP 50 mg/25 mg and 100 mg/25 mg from the United States Food and Drug Administration (USFDA) to market a generic version of TENORETIC (atenolol and chlorthalidone) Tablets of Alvogen Malta Operations Ltd.
Atenolol and Chlorthalidone Tablets are indicated for the treatment of hypertension, to lower blood pressure.
The product will be commercialized from Unichem's Ghaziabad Plant.
Read also: Unichem Labs to step up API production
Unichem Laboratories Limited is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in several markets across the world.
Read also: Unichem Labs gets USFDA nod to Tolterodine Tartrate Tablet to treat overactive bladder

Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our Terms of Use, Privacy Policy, and Advertisement Policy.
For further details, please review our Full Disclaimer.

0 Comments

Post a comment

Please login to post a comment.

No comments yet. Be the first to comment!